Skip to main content
OpenTrials

Clinical trial condition

Nevi and Melanomas

Explore clinical trials studying Nevi and Melanomas. Study availability and eligibility vary by location and protocol.

2,368 public trials 407 recruiting studies
Refine in advanced search Browse all conditions

Nevi and Melanomas trial results

Completed

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734

Conditions
Melanoma, Metastatic Melanoma, Neoplasms, +10 more
Locations
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • Watson Clinic Center for Cancer Care and Research Lakeland, Florida, United States
  • Florida Hospital Cancer Institute Orlando, Florida, United States
  • Gulfcoast Oncology Associates St. Petersburg, Florida, United States
View all 15 locations
View Trial Details
Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

NCT03319459

Conditions
Adenocarcinoma, Advanced Solid Tumors, Breast Diseases, +63 more
Locations
  • UCSD Moores Cancer Center San Diego, California, United States
  • University of Minnesota Minneapolis, Minnesota, United States
  • The Ohio State University James Cancer Hospital Columbus, Ohio, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
View Trial Details
Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

NCT03178851

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • HonorHealth Research Institute - Bisgrove Scottsdale, Arizona, United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 43 locations
View Trial Details
Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075

Conditions
Cutaneous Melanoma, Eye Diseases, Eye Neoplasms, +25 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Mount Sinai Hospital New York, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details

Related conditions